Novo Nordisk's Share Buyback Defies a Challenging Outlook

Novo Nordisk spends billions on share buybacks despite forecasting a 5-13% sales and profit decline for 2026. Stock is down 27% YTD, with key catalysts in obesity drug coverage and pricing ahead.

Novo Nordisk is deploying billions of kroner to repurchase its own stock even as its financial forecast darkens. The Danish pharmaceutical giant has acquired approximately 11 million B shares since its current program began on February 4, 2026, spending a total of around DKK 2.84 billion at an average price of DKK 257.56 per share. This aggressive capital return persists despite the company anticipating a significant drop in its underlying performance this year.

Operationally, the maker of Wegovy and Ozempic faces substantial headwinds. For 2026, management expects a currency-adjusted decline in both sales and operating profit of between five and thirteen percent. This bleak outlook is driven by intensifying competition in the global GLP-1 market, sustained price adjustments in key regions, and rising research and development costs. A one-time benefit of $4.2 billion from reversed U.S. 340B discounts is propping up the reported figures, masking the underlying pressure on margins.

The stock's performance reflects these challenges. Shares have fallen more than 27% since the start of the year, trading around 31.98 euros and hovering near a 52-week low. The technical picture is weak, with the price languishing well below its 200-day moving average. A Relative Strength Index reading of just under 20 indicates the equity is deeply oversold.

This buyback activity is part of a much larger framework. Novo Nordisk has committed to investing up to DKK 15 billion in its own shares over a twelve-month period. The current tranche, which runs until May 4, 2026, is capped at DKK 3.8 billion. Following the recent transactions, the company's treasury holds roughly 28.4 million B shares, equivalent to 0.6% of its total share capital.

Investors are now looking to several mid-year milestones for potential catalysts. The commercial uptake data for the oral version of Wegovy, due with the quarterly report in May, will be closely watched. A critical development is the expected mid-2026 start of Medicare Part D coverage for obesity medications in the United States, which could significantly expand patient access. Furthermore, a key pricing event looms on August 31, 2026, when an introductory offer for the 4mg dose expires, raising its price from $149 to the standard $199.

Beyond its core metabolic business, Novo Nordisk is pursuing pipeline diversification. The Phase 3 EVOKE study is investigating oral semaglutid for early Alzheimer's disease, while higher-dose weight-loss formulations have now achieved broad availability in the U.S. market. The company's sustained share repurchases in the face of operational decline signal a calculated bet that these future opportunities, coupled with strategic pricing and market expansion, can ultimately offset the current competitive storm.